The stellate cell is the principal cell type involved in hepatic fibrogenesis and on stimulation contracts, a state that is characterized by the increased expression of the contractile filament protein, alpha smooth muscle actin [
30,
31]. We have demonstrated that culturing LX2 cells with FXa or thrombin independently and in combination results in stellate cell contraction. FXa concentration used (0.5 U/ml or 174 nM) was within the plasma physiological range (~ 150-200 nM). There is an upregulation in procollagen, TGF-beta and αSMA gene expression only when FXa and Thrombin in combination were given. These results are corroborated by our gel contraction assay, in which we were able to quantify a highly significant increase in gel contraction when FXa and thrombin were administered in combination compared to alone. Both the upregulation of procollagen, TGF-Beta, and αSMA and the contraction of LX2 cells in culture and gel contraction assays confirm FXa and thrombin independently potentiate HSC activation and in synergy this is significantly increased
. A potential mode of action for these proteins can be postulated. Thrombin is known to be a mediator of stellate cell activation [
18] and it is now established that the cellular actions of thrombin are in part mediated by PAR signaling [
14]. PAR receptors are a family of widely expressed G-protein-coupled receptors, that transduce transmembrane signaling and four PARs have been identified [
32]. PAR-1 and -3 are both preferentially activated by thrombin. PAR-4 has reduced affinity and PAR-2 is resistant to thrombin activation. A substantial body of evidence from in vivo and in vitro studies is now accumulating to suggest PAR-1 activation leads to HSC activation [
5,
33‐
35]. Whilst thrombin PAR-1 mediated ligation results in stellate cell activation, the mechanism by which fibroblasts are activated by FXa has been less well studied. FXa, is a coagulation factor generated at the point of convergence of the intrinsic and extrinsic coagulation pathways and responsible for the conversion of prothrombin to thrombin. Recent evidence suggests that FXa activates PAR-1, in a similar fashion to thrombin, but also has been demonstrated to activate PAR-2 [
36,
37]. In pulmonary fibrosis which is a well-documented paradigm for liver fibrosis, FXa mediated PAR1 activation has been demonstrated [
20]. PAR-2 expression has recently been demonstrated on both hepatic stellate cells [
1,
34,
35]: up-regulated in fibrotic livers [
1]. PAR-2 deficiency, using PAR-2 knockout mice, has been shown to reduce CCL4 induced liver fibrosis [
38]. FXa via the added role of PAR-2 mediated activation could explain the increased effect on stellate cell contraction and activation demonstrated with FXa or FXa with thrombin, compared to thrombin alone. In vivo FXa is also central in converting prothrombin to thrombin, with one molecule of FXa generating a ‘thrombin burst’ of over 1000 thrombin molecules [
39]. Therefore FXa is pro-fibrotic by two pathways. Firstly it drives thrombin production and secondly, independent of its pro-coagulant activity, we have demonstrated it potentiates activation of stellate cells, but further experiments are required to confirm if this is via PAR-1 and PAR-2 mediated mechanisms.